Pricing

Citigroup Funding ELKS 11.00% Celgene Corp. due 4/6/2009 (EHC)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
NATIONAL COMMERCIAL BANKS
388 GREENWICH STREET NEW YORK, NY 10013

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Are you looking for this stock instead?

Citigroup Funding Inc., 11.00% ELKS (Equity LinKed Securities) based on the common stock of Celgene Corp. (Nasdaq: CELG), due 4/6/2009, and issued at $10 per ELKS. The ELKS pay a total of $1.1275 in cash composed of $0.3049 in interest and $0.8226 in option premium, which is payable on 10/6/2008 and 4/6/2009 to holders of record at the close of business on the third business day prior to the payment date. At maturity the holder will receive either 0.16589 common shares of Celgene if the price of Celgene's shares at any time during the term of the ELKS is less than or equal to $36.17 (60% of the initial share price of $60.28 on 3/24/2008) or $10 in cash. The holder also has the right to elect to receive the cash value of the shares due at maturity. The ELKS are NOT principal protected and at maturity the holder could receive common shares or cash whose value is less, and possibly significantly less, than the original investment in the ELKS.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available